Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2013

Open Access 01-12-2013 | Research

L1 and epithelial cell adhesion molecules associated with gastric cancer progression and prognosis in examination of specimens from 601 patients

Authors: Yuan-Yu Wang, Li Li, Zhong-Sheng Zhao, Yong-Xiang Wang, Zai-Yuan Ye, Hou-Quan Tao

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2013

Login to get access

Abstract

Background

L1 cell adhesion molecule (L1CAM) and epithelial cell adhesion molecule (EPCAM) have been implicated in the development and progression of gastric cancer. The present study investigated the clinical significance of L1CAM and EPCAM in the development, progression and prognosis of gastric cancer.

Methods

Expression of L1CAM and EPCAM were examined immunochemically in 601 clinicopathologically characterized gastric cancer cases.

Results

L1CAM protein was detected in 23.9% of human non-tumor mucosa samples. All samples expressed L1CAM protein at low levels. High expression of L1CAM protein was detected in 163 (27.1%) tumors. Expression of L1CAM correlated with age, tumor location, size of tumors, Lauren’s classification, depth of invasion, lymph node and distant metastases, regional lymph node stage, Tumor-Node-Metastasis (TNM) stage and prognosis. EPCAM protein was detected in 45.7% of human non-tumor mucosa samples. All samples expressed EPCAM protein at low levels. High expression of EPCAM protein was detected in 247 (41.1%) tumors. Expression of EPCAM correlated with age, tumor location, size of tumors, Lauren’s classification, depth of invasion, lymph node and distant metastases, regional lymph node stage, TNM stage and prognosis. Cumulative 5-year survival rates of patients with high expression of both L1CAM and EPCAM were significantly lower than in patients with low expression of both.

Conclusions

Expression of L1CAM and EPCAM in gastric cancer was significantly associated with lymph node and distant metastasis, and poor prognosis. L1CAM and EPCAM proteins could be useful markers to predict tumor progression and prognosis.
Appendix
Available only for authorised users
Literature
1.
Lee HS, Lee HK, Kim HS, et al: Tumour suppressor gene expression correlates with gastric cancer prognosis. J Pathol. 2003, 200: 39-46. 10.1002/path.1288.CrossRef
2.
Lee HS, Lee HK, Kim HS, et al: MUC1, MUC2, MUC5AC, and MUC6 expressions in gastric carcinomas: their roles as prognostic indicators. Cancer. 2001, 92: 1427-34. 10.1002/1097-0142(20010915)92:6<1427::AID-CNCR1466>3.0.CO;2-L.CrossRef
3.
Kolev Y, Uetake H, Iida S, et al: Prognostic significance of VEGF expression in correlation with COX-2, microvessel density and clinicopathological characteristics in human gastric carcinoma. Ann Surg Oncol. 2007, 14: 2738-47. 10.1245/s10434-007-9484-7.CrossRef
4.
Mizokami K, Kakeji Y, Oda S, et al: Clinicopathologic significance of hypoxia-inducible factor 1 alpha overexpression in gastric carcinomas. J Surg Oncol. 2006, 94: 149-154. 10.1002/jso.20568.CrossRef
5.
Song LB, Liao WT, Mai HQ, et al: The clinical significance of twist expression in nasopharyngeal carcinoma. Cancer Lett. 2006, 242: 258-65. 10.1016/j.canlet.2005.11.013.CrossRef
6.
Geisler SA, Olshan AF, Weissler MC, et al: p16 and p53 protein expression as prognostic indicators of survival and disease recurrence from head and neck cancer. Clin Cancer Res. 2002, 8: 3445-53.
7.
Fukuoka J, Fujii T, Shih JH, et al: Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer. Clin Cancer Res. 2004, 10: 4314-24. 10.1158/1078-0432.CCR-03-0489.CrossRef
8.
Shiraishi N, Sato K, Yasuda K, et al: Multivariate prognostic study on large gastric cancer. J Surg Oncol. 2007, 96: 14-18. 10.1002/jso.20631.CrossRef
9.
Raveh S, Gavert N, Ben-Ze’ev A: L1 cell adhesion molecule (L1CAM) in invasive tumors. Cancer Lett. 2009, 282 (2): 137-45. 10.1016/j.canlet.2008.12.021.CrossRef
10.
Gavert N, Ben-Shmuel A, Raveh S, Ben-Ze’ev A: L1-CAM in cancerous tissues. Expert Opin Biol Ther. 2008, 8 (11): 1749-57. 10.1517/14712598.8.11.1749.CrossRef
11.
Rawnaq T, Kleinhans H, Uto M, et al: Subset of esophageal adenocarcinoma expresses adhesion molecule l1 in contrast to squamous cell carcinoma. Anticancer Res. 2009, 29 (4): 1195-9.
12.
Bergmann F, Wandschneider F, Sipos B, et al: Elevated L1CAM expression in precursor lesions and primary and metastastic tissues of pancreatic ductal adenocarcinoma. Oncol Rep. 2010, 24 (4): 909-15.
13.
Ben QW, Wang JC, Liu J, et al: Positive expression of L1-CAM is associated with perineural invasion and poor outcome in pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2010, 17 (8): 2213-21. 10.1245/s10434-010-0955-x.CrossRef
14.
Kajiwara Y, Ueno H, Hashiguchi Y, et al: Expression of l1 cell adhesion molecule and morphologic features at the invasive front of colorectal cancer. Am J Clin Pathol. 2011, 136 (1): 138-44. 10.1309/AJCP63NRBNGCTXVF.CrossRef
15.
Choi SY, Jo YS, Huang SM, et al: L1 cell adhesion molecule as a novel independent poor prognostic factor in gallbladder carcinoma. Hum Pathol. 2011, 42 (10): 1476-83. 10.1016/j.humpath.2011.01.003.CrossRef
16.
Li S, Jo YS, Lee JH, et al: L1 cell adhesion molecule is a novel independent poor prognostic factor of extrahepatic cholangiocarcinoma. Clin Cancer Res. 2009, 15 (23): 7345-51. 10.1158/1078-0432.CCR-09-0959.CrossRef
17.
Kodera Y, Nakanishi H, Ito S, et al: Expression of L1 cell adhesion molecule is a significant prognostic factor in pT3-stage gastric cancer. Anticancer Res. 2009, 29 (10): 4033-9.
18.
Min JK, Kim JM, Li S, et al: L1 cell adhesion molecule is a novel therapeutic target in intrahepatic cholangiocarcinoma. Clin Cancer Res. 2010, 16 (14): 3571-80. 10.1158/1078-0432.CCR-09-3075.CrossRef
19.
Tsutsumi S, Morohashi S, Kudo Y, et al: L1 Cell adhesion molecule (L1CAM) expression at the cancer invasive front is a novel prognostic marker of pancreatic ductal adenocarcinoma. J Surg Oncol. 2011, 103 (7): 669-73. 10.1002/jso.21880.CrossRef
20.
Kato K, Maesawa C, Itabashi T, et al: DNA hypomethylation at the CpG island is involved in aberrant expression of the L1 cell adhesion molecule gene in colorectal cancer. Int J Oncol. 2009, 35 (3): 467-76.
21.
Shigdar S, Lin J, Yu Y, et al: RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer Sci. 2011, 102 (5): 991-8. 10.1111/j.1349-7006.2011.01897.x.CrossRef
22.
Kimura H, Kato H, Faried A, et al: Prognostic significance of EpCAM expression in human esophageal cancer. Int J Oncol. 2007, 30 (1): 171-9.
23.
Fong D, Steurer M, Obrist P, et al: Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance. J Clin Pathol. 2008, 61 (1): 31-5.CrossRef
24.
Went P, Vasei M, Bubendorf L, et al: Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer. 2006, 94 (1): 128-35. 10.1038/sj.bjc.6602924.CrossRef
25.
Wenqi D, Li W, Shanshan C, et al: EpCAM is overexpressed in gastric cancer and its downregulation suppresses proliferation of gastric cancer. J Cancer Res Clin Oncol. 2009, 135 (9): 1277-85. 10.1007/s00432-009-0569-5.CrossRef
26.
Songun I, Litvinov SV, van de Velde CJ, et al: Loss of Ep-CAM (CO17-1A) expression predicts survival in patients with gastric cancer. Br J Cancer. 2005, 92 (9): 1767-72. 10.1038/sj.bjc.6602519.CrossRef
27.
Akita H, Nagano H, Takeda Y, et al: Ep-CAM is a significant prognostic factor in pancreatic cancer patients by suppressing cell activity. Oncogene. 2011, 30 (31): 3468-76. 10.1038/onc.2011.59.CrossRef
28.
Saito H, Fukumoto Y, Osaki T, et al: Prognostic significance of level and number of lymph node metastases in patients with gastric cancer. Ann Surg Oncol. 2007, 14 (5): 1688-93. 10.1245/s10434-006-9314-3.CrossRef
29.
Hidaka H, Eto T, Maehara N, et al: Comparative effect of lymph node metastasis classified by the anatomical site or by the number of nodes involved on prognosis of patients with gastric cancer. Hepatogastroenterology. 2008, 55 (88): 2269-2272.
30.
Lauren P: The two histological main types of gastric cancer: diffuse and so-called intestinal type carcinoma. Acta Pathol Microbiol Scand. 1965, 64: 31-9.
31.
Fuchs CS, Mayer RJ: Gastric carcinoma. N Engl J Med. 1995, 333 (1): 32-41. 10.1056/NEJM199507063330107.CrossRef
Metadata
Title
L1 and epithelial cell adhesion molecules associated with gastric cancer progression and prognosis in examination of specimens from 601 patients
Authors
Yuan-Yu Wang
Li Li
Zhong-Sheng Zhao
Yong-Xiang Wang
Zai-Yuan Ye
Hou-Quan Tao
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2013
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-32-66

Other articles of this Issue 1/2013

Journal of Experimental & Clinical Cancer Research 1/2013 Go to the issue

Research

Activation of NF-κB by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines

Research

Candidate microRNA biomarkers of pancreatic ductal adenocarcinoma: meta-analysis, experimental validation and clinical significance

Research

Dose evaluation for skin and organ in hepatocellular carcinoma during angiographic procedure

Research

Detection of doublecortin domain-containing 2 (DCDC2), a new candidate tumor suppressor gene of hepatocellular carcinoma, by triple combination array analysis

Research

EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells

Research

Expression of deleted in liver cancer 1 and plasminogen activator inhibitor 1 protein in ovarian carcinoma and their clinical significance
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits